| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
81,510,000 |
| Market
Cap: |
1.73(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$17.69 - $45.07 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Beam Therapeutics is a biotechnology company. Co. has identified four development candidates to date: three from its ex vivo platform, with two candidates targeting hemoglobinopathies and one candidate targeting T-cell leukemia, and one from its in vivo platform targeting glycogen storage disease. BEAM-102 directly corrects the causative mutation in sickle cell disease by recreating a naturally-occurring normal human hemoglobin variant, HbG-Makassar. BEAM-201 is an anti-CD7, multiplex edited, allogeneic chimeric antigen receptor T cell development candidate for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
1,016,735 |
1,088,642 |
1,249,399 |
1,617,862 |
| Total Sell Value |
$31,322,673 |
$33,197,856 |
$38,301,409 |
$55,212,492 |
| Total People Sold |
6 |
6 |
6 |
6 |
| Total Sell Transactions |
9 |
12 |
17 |
40 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ciaramella Giuseppe |
President and CSO |
• – – |
2023-07-21 |
4 |
AS |
$32.06 |
$4,979,687 |
D/D |
(155,324) |
48,250 |
|
-7% |
|
| Ciaramella Giuseppe |
President and CSO |
• – – |
2023-07-21 |
4 |
OE |
$7.22 |
$659,070 |
D/D |
91,284 |
203,574 |
|
- |
|
| Simon Amy |
Chief Medical Officer |
• – – |
2023-07-10 |
4 |
AS |
$30.48 |
$11,918 |
D/D |
(391) |
68,917 |
|
-23% |
|
| Bellon Christine |
Chief Legal Officer |
• – – |
2023-04-04 |
4 |
AS |
$29.09 |
$33,777 |
D/D |
(1,161) |
82,790 |
|
-15% |
|
| Evans John M. |
CEO |
• • – |
2023-04-04 |
4 |
AS |
$29.09 |
$188,904 |
D/D |
(6,493) |
1,117,979 |
|
-15% |
|
| Burrell Terry-Ann |
Chief Financial Officer |
• – – |
2023-04-04 |
4 |
AS |
$29.09 |
$63,598 |
D/D |
(2,186) |
47,117 |
|
-15% |
|
| Ciaramella Giuseppe |
President & CSO |
• – – |
2023-04-04 |
4 |
AS |
$29.09 |
$51,029 |
D/D |
(1,754) |
112,290 |
|
-15% |
|
| Simon Amy |
Chief Medical Officer |
• – – |
2023-04-04 |
4 |
AS |
$29.09 |
$346,115 |
D/D |
(11,654) |
69,308 |
|
-15% |
|
| Bellon Christine |
Chief Legal Officer |
• – – |
2023-04-03 |
4 |
AS |
$30.31 |
$28,219 |
D/D |
(931) |
83,951 |
|
-15% |
|
| Evans John M. |
CEO |
• • – |
2023-04-03 |
4 |
AS |
$30.31 |
$156,430 |
D/D |
(5,161) |
1,124,472 |
|
-15% |
|
| Burrell Terry-Ann |
Chief Financial Officer |
• – – |
2023-04-03 |
4 |
AS |
$30.31 |
$74,381 |
D/D |
(2,454) |
49,303 |
|
-15% |
|
| Ciaramella Giuseppe |
President & CSO |
• – – |
2023-04-03 |
4 |
AS |
$30.31 |
$58,135 |
D/D |
(1,918) |
114,044 |
|
-15% |
|
| Simon Amy |
Chief Medical Officer |
• – – |
2023-04-03 |
4 |
AS |
$30.31 |
$134,728 |
D/D |
(4,445) |
80,962 |
|
-15% |
|
| Simon Amy |
Chief Medical OfficerOfficer |
• – – |
2023-03-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
65,129 |
|
-10% |
|
| Burrell Terry-Ann |
Chief Financial Officer |
• – – |
2023-01-27 |
4 |
AS |
$45.08 |
$1,629,747 |
D/D |
(36,152) |
31,277 |
|
-24% |
|
| Burrell Terry-Ann |
Chief Financial Officer |
• – – |
2023-01-27 |
4 |
OE |
$13.68 |
$494,559 |
D/D |
36,152 |
67,429 |
|
- |
|
| Burrell Terry-Ann |
Chief Financial Officer |
• – – |
2023-01-26 |
4 |
AS |
$45.16 |
$49,763 |
D/D |
(1,102) |
31,277 |
|
-22% |
|
| Burrell Terry-Ann |
Chief Financial Officer |
• – – |
2023-01-26 |
4 |
OE |
$13.68 |
$15,075 |
D/D |
1,102 |
32,379 |
|
- |
|
| Burrell Terry-Ann |
Chief Financial Officer |
• – – |
2023-01-24 |
4 |
AS |
$45.01 |
$666,657 |
D/D |
(14,810) |
31,277 |
|
-24% |
|
| Burrell Terry-Ann |
Chief Financial Officer |
• – – |
2023-01-24 |
4 |
OE |
$13.68 |
$202,601 |
D/D |
14,810 |
46,087 |
|
- |
|
| Burrell Terry-Ann |
Chief Financial Officer |
• – – |
2023-01-23 |
4 |
AS |
$45.02 |
$244,290 |
D/D |
(5,426) |
31,277 |
|
-27% |
|
| Burrell Terry-Ann |
Chief Financial Officer |
• – – |
2023-01-23 |
4 |
OE |
$13.68 |
$74,228 |
D/D |
5,426 |
36,703 |
|
- |
|
| Burrell Terry-Ann |
Chief Financial Officer |
• – – |
2023-01-18 |
4 |
AS |
$45.14 |
$2,130,382 |
D/D |
(47,195) |
31,277 |
|
-27% |
|
| Burrell Terry-Ann |
Chief Financial Officer |
• – – |
2023-01-18 |
4 |
OE |
$13.68 |
$545,640 |
D/D |
39,886 |
78,472 |
|
- |
|
| Ciaramella Giuseppe |
President & CSO |
• – – |
2023-01-03 |
4 |
AS |
$37.14 |
$2,012,490 |
D/D |
(53,729) |
95,962 |
|
-11% |
|
169 Records found
|
|
Page 2 of 7 |
|
|
0.83 (3.76%) 
